Early Diagnosis of Breast Cancer Improves Survival

The accurate detection and characterization of the disease made it possible to classify breast cancer into a number of subtypes using markers. This classification uses a combination of molecular and clinical parameters to predict the likelihood of recurrence, the effectiveness of treatment, and the prognosis.

Breast cancer is the second leading cause of cancer-related deaths in women worldwide and accounts for more than 1 in 10 new cancer diagnoses each year. Breast cancer has now overtaken lung cancer as the most commonly diagnosed cancer worldwide. The leading cause of cancer in women is breast cancer.

Globally, 2.3 million women received a breast cancer diagnosis in 2020, and 685,000 of them passed away. As of the end of 2020, 7.8 million women were diagnosed with breast cancer in the last five years, making it the most common cancer in the world. Globally, women lose more disability-adjusted life years (DALYs) to breast cancer than to any other cancer. Breast cancer occurs in women of all ages after puberty in all countries of the world, but with increasing frequency later in life. Breast cancer mortality has changed little from the 1930s to the 1970s. Improving survival began in the 1980s in countries with early detection programs combined with various therapies to eradicate the invasive disease.

This is primarily due to a lack of awareness, late diagnosis, lack of adequate breast cancer screening programs, and social stigma. If breast cancer is detected early and accurately, the survival rate is high and the treatment success rate is high. Breast cancer is more likely to be treated successfully if it is detected early when it has not spread. Early detection measures can reduce mortality from breast cancer. It is imperative to increase knowledge about the benefits of breast screening for hyperplasia and improve access to screening facilities for early detection, thereby reducing associated costs.
It is used to determine if you are at risk of certain types of cancer. These tests help determine the likelihood of developing cancer. They can also be used to determine if a person should undergo further screening or take preventative measures. Molecular diagnostics is a fundamental part of precision medicine, an approach that allows individuals to receive the optimal treatment for their particular health condition based on the analysis of DNA, RNA, proteins, or related molecules.

In recent years, many genes have been identified, including BRCA1, BRCA2, c-myc, erbB2, HER-2, and p53, whose variants are associated with increased breast cancer risk. Identifying these genes together with molecular genetic analysis will not only greatly improve diagnosis, but also help clinicians determine appropriate therapy.

Rapid diagnosis should be combined with effective cancer treatment, which in many situations requires some degree of specialized cancer care. By using breast cancer as a model to establish centralized services in cancer facilities and hospitals, we can optimize treatment for breast cancer while improving treatment for other types of cancer.